Special Issue "Advances and Future Perspectives in Diagnosis and Treatment of Urothelial Cell Carcinoma"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: 30 June 2022.

Special Issue Editors

Dr. Andrea Mari
E-Mail Website
Guest Editor
Department of Experimental and Clinical Medicine, Unit of Oncologic Minimally-Invasive Urology and Andrology, Careggi University Hospital, University of Florence, Florence, Italy.
Interests: Urothelial clinical biomarkers; Prognostication; Endoscopic surgery; Robotics
Dr. Benjamin Pradere
E-Mail Website
Guest Editor
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
Interests: onco-urology; Bladder cancer; UTUC; robotic surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Jeremy Yuen-Chun Teoh
E-Mail Website
Guest Editor
Division of Urology, Department of Surgery, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
Interests: bladder cancer; prostate cancer

Special Issue Information

Dear Colleagues,

The field of research in urothelial cancer has seen significant advances in recent years from diagnosis to treatment, as well as the implementation of prognostic models.

In detail, next-generation sequencing technologies have allowed us to deeply understand the genes most involved in bladder cancer pathogenesis. Non-invasive methods of diagnosis, including liquid biopsies, have seen major advances as well. However, most of these innovative tools need clinical validation.

Moreover, the use of immune checkpoint inhibitor drugs has brought a revolutionary therapeutic approach in patients with advanced and metastatic urothelial cancer.

In parallel, in the last decade, robotic surgery has increasingly been adopted for the treatment of bladder cancer and upper tract urothelial carcinoma with the purpose of decreasing treatment-related morbidity. Lastly, several predictive nomograms and prognostic models have been proposed to improve patient selection and more accurately forecast oncologic outcomes.

Overall, although these developments may provide benefits in terms of improved survival and quality of life, there are several unmet needs before we can effectively cure patients with urothelial cancer and reduce the levels of morbidity associated with treatments.

This Special Issue aims to explore diagnostic and therapeutic advances in the treatment of urothelial carcinoma, including bladder, upper tract, and urethral tumors.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: novel diagnostic tools for bladder cancer, insights in molecular biology of bladder cancer, biomarkers in urothelial cancer, innovative imaging modalities in diagnosis and staging, bladder-sparing treatment options in muscle-invasive bladder cancer, minimally invasive approaches to bladder and upper tract urothelial carcinomas, systemic therapy for high risk urothelial cancers, and predictive and prognostic models in bladder cancer and urethral cancer.

We look forward to receiving your contributions.

Dr. Andrea Mari
Dr. Benjamin Pradere
Dr. Jeremy Yuen-Chun Teoh
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Biomarkers
  • Diagnosis
  • Imaging
  • Nomogram
  • Prognosis
  • Robotics
  • Urothelial cancer

Published Papers

This special issue is now open for submission.
Back to TopTop